Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in Migraine Prevention (Study 305)
NCT03732638Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rimegepant Arm with Placebo Arm (2 arms). Primary endpoint: Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03732638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732638.